Brigitte Assouline

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: Cytheris, Ogd2 Pharma, Centre National De La Recherche Scientifique. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brigitte Assouline. Retrieved from https://idiyas.com/inventor/brigitte-assouline

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 39(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

4. 1 out of 6

Institut De Cancerologie De L'ouest

patents

5. 1 out of 1,853

National Institute of Health and Medical Research

patents

6. 1 out of 156

The University of Nantes

patents

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11697689 - Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs (2023-07-11),

2. 11440968 - Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2) (2022-09-13),

3. 8153114 - Hyperglycosylated mammalian IL-7 IgG conjugate composition (2012-04-10),

4. 8034327 - Hyperglycosylated IL-7, preparation and uses (2011-10-11),

5. 7708985 - Glycosylated IL-7, preparation and uses (2010-05-04),

6. 7585947 - IL-7 drug substance, composition, preparation and uses (2009-09-08),

Title: Brigitte Assouline: Innovator in Cancer Therapeutics

Introduction

Brigitte Assouline is a prominent inventor based in Courbevoie, France. She has made significant contributions to the field of cancer therapeutics, holding a total of 6 patents. Her innovative work focuses on the use of antibodies to enhance the effectiveness of anti-cancer agents.

Latest Patents

Among her latest patents is a method for the delivery of an anti-cancer agent into cells expressing the O-acetylated GD2 ganglioside. This method utilizes an antibody that specifically recognizes the OAcGD2 ganglioside, thereby improving the therapeutic potential of drugs. Another notable patent involves a humanized antibody against O-acetylated GD2 ganglioside, which includes a humanized light chain variable region and a humanized heavy chain variable region. This antibody has applications in both diagnostics and therapy.

Career Highlights

Brigitte has worked with several companies throughout her career, including Cytheris and Ogd2 Pharma. Her experience in these organizations has allowed her to develop and refine her innovative ideas in cancer treatment.

Collaborations

Brigitte has collaborated with notable individuals in her field, including Michel Christian Morre and Anne Gregoire. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Brigitte Assouline is a trailblazer in the realm of cancer therapeutics, with a strong portfolio of patents that reflect her dedication to improving treatment options. Her work continues to inspire advancements in medical science.

Profile summary based on public USPTO records.